Currently Enrolling Trials
Simulect has been approved for acute rejection episodes in renal transplant recipients.
Mechanism of Action
Simulect works by blocking the receptor for IL-2, a protein that simulates proliferation of T-lymphocytes, which play a key role in organ transplant rejection.
Approval Date: 1998-05-01
Company Name: Novartis